FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted ...

Opus Genetics reports positive Phase 3 trial results for Phentolamine Ophthalmic Solution 0.75% in treating presbyopia. Quiver AI Summary Opus Genetics, Inc. announced positive topline results ...

STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or ...